Advertisement

Angiogenesis

, Volume 1, Issue 2, pp 142–154 | Cite as

Matrix metalloproteinase inhibitors

  • Peter D. Brown
Article

Abstract

Matrix metalloproteinases (MMPs) are a family of structurally related enzymes that are capable of degrading a wide variety of extracellular matrix proteins. In addition to the role played by these enzymes in normal tissue remodeling, MMPs have been implicted in the pathogenesis of diseases such as rheumatoid arthritis and multiple sclerosis. In cancer increased MMP activity may facilitate tumor invasion, metastasis and tumor angiogenesis. Expression of high levels of MMPs in certain malignancies has been shown to be associated with a poor prognosis. Using structure-based design, a range of low molecular weight synthetic MMP inhibitors have been developed. These have proven effective in animal models of disease and several (CGS 27023A, AG3340, Ro 32-3555 and marimastat) have now commenced clinical trials.

Cancer clinical trials matrix metalloproteinase metastasis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enz Prot 1996; 49, 117–137.Google Scholar
  2. 2.
    Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Different Dev 1990; 32, 319–328.CrossRefGoogle Scholar
  3. 3.
    Mikkelsen T, Yan PS, Ho KL, Sameni M, Sloane BF, Rosenblum ML. Immunolocalization of cathepsin B in human glioma—implications for tumor invasion and angiogenesis. J Neurosurg 1995; 83, 285–290.PubMedCrossRefGoogle Scholar
  4. 4.
    Sinha AA, Gleason DF, Staley NA, Wilson MJ, Sameni M, Sloane BF. Cathepsin B in angiogenesis of human prostate—an immunohistochemical and immunoelectron microscopic analysis. Anat Rec 1995; 241, 353–362.PubMedCrossRefGoogle Scholar
  5. 5.
    Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: requirements for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989; 108, 671–682.PubMedCrossRefGoogle Scholar
  6. 6.
    Pepper MS, Montesano R, Mandriota SJ, Orci L, Vassalli JD. Angiogenesis—a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enz Prot 1996; 49, 138–162.Google Scholar
  7. 7.
    Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990; 1, 99–106.PubMedGoogle Scholar
  8. 8.
    Gordon JL, Drummond, AH, Galloway WA. Metalloproteinase inhibitors as therapeutics. Clin Exp Rheumatol 1993; 11, S91–94.PubMedGoogle Scholar
  9. 9.
    Wilhelm SC, Eisen AZ, Teter M, Clark SD, Kronberger A, Goldberg G. Human fibroblast collagenase: glycosylation and tissue-specific levels of enzyme synthesis. Proc Natl Acad Sci USA 1986; 83, 3756–3760.PubMedCrossRefGoogle Scholar
  10. 10.
    Hasty KA, Pourmotabbed TF, Goldberg GI, et al. Human neutrophil collagenase; a distinct gene product with homology to other matrix metalloproteinases. J Biol Chem 1990; 265, 11421–11424.PubMedGoogle Scholar
  11. 11.
    Freije JM, Diez-Itza I, Balbin M, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269, 16766–16773.PubMedGoogle Scholar
  12. 12.
    Collier IE, Wilhelm SM, Eisen AZ, et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1988; 263, 6579–6587.PubMedGoogle Scholar
  13. 13.
    Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. SV40-transformed human lung fibroblasts secrete a 92-kDa Type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264, 17213–17221.PubMedGoogle Scholar
  14. 14.
    Liotta LA, Tryggvason K, Garbisa S, Robey PG, Abe S. Partial purification and characterisation of a neutral protease which cleaves type IV collagen. Biochemistry 1981; 20, 100–104.PubMedCrossRefGoogle Scholar
  15. 15.
    Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG. Human 92-and 72-kilodalton type IV collagenases are elastases. J Biol Chem 1991; 266, 7870–7875.PubMedGoogle Scholar
  16. 16.
    Eble JA, Ries A, Lichy A, et al. The recognition sites of the integrins alpha1beta1 and alpha2beta1 within collagen IV are protected against gelatinase A attack in the native protein. J Biol Chem 1996; 271, 30964–30970.PubMedCrossRefGoogle Scholar
  17. 17.
    Wilhelm SM, Collier IE, Kronberger A, et al. Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumourigenic cells. Proc Natl Acad Sci USA 1987; 84, 6725–6729.PubMedCrossRefGoogle Scholar
  18. 18.
    Muller D, Quantin B, Gesnel MC, Millon-Collard R, Abecassis J, Breathnach R. The collagenase gene family in humans consists of at least four members. Biochem J 1988; 253, 187–192.PubMedGoogle Scholar
  19. 19.
    Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cell of breast carcinomas. Nature 1990; 348, 699–704.PubMedCrossRefGoogle Scholar
  20. 20.
    Pei D, Majmudar G, Weiss SJ. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem 1994; 269, 25849–25855.PubMedGoogle Scholar
  21. 21.
    Quantin B, Murphy G, Breathnach R. Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members. Biochemistry 1989; 28, 5325–5334.CrossRefGoogle Scholar
  22. 22.
    Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterisation of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 1993; 268, 23824–23829.PubMedGoogle Scholar
  23. 23.
    Chandler S, Cossins J, Lury J, Wells G. Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour-necrosis factor-α fusion protein. Biochem Biophys Res Commun 1996; 228, 421–429.PubMedCrossRefGoogle Scholar
  24. 24.
    Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994; 370, 61–65.PubMedCrossRefGoogle Scholar
  25. 25.
    Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 1995; 231, 602–608.PubMedCrossRefGoogle Scholar
  26. 26.
    Takino T, Sato H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem 1995; 270, 23013–23020.PubMedCrossRefGoogle Scholar
  27. 27.
    Puente XS, Pendas AM, Llano E, Velasco G, Lopez-Otin C. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996; 56, 944–949.PubMedGoogle Scholar
  28. 28.
    Strongin A, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72 kDa type IV collagenase. J Biol Chem 1995; 270, 5331–5338.PubMedCrossRefGoogle Scholar
  29. 29.
    Ohuchi E, Imai K, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997; 272, 2446–2451.PubMedCrossRefGoogle Scholar
  30. 30.
    Cossins J, Dudgeon TJ, Catlin G, Gearing AJH, Clements JM. Identification of MMP-18, a putative novel human matrix metalloproteinase. Biochem Biophys Res Commun 1996; 228, 494–498.PubMedCrossRefGoogle Scholar
  31. 31.
    Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-a precursor by metalloproteinases. Nature 1994; 370, 555–557.PubMedCrossRefGoogle Scholar
  32. 32.
    Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells. Nature 1997; 385, 729–733.PubMedCrossRefGoogle Scholar
  33. 33.
    Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385, 733–736.PubMedCrossRefGoogle Scholar
  34. 34.
    Kleiner DE, Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteinases. Curr Opin Cell Biol 1993; 5, 891–897.PubMedCrossRefGoogle Scholar
  35. 35.
    Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995; 375, 244–247.PubMedCrossRefGoogle Scholar
  36. 36.
    Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix degrading activity. J Biol Chem 1996; 271, 9135–9140.PubMedCrossRefGoogle Scholar
  37. 37.
    Docherty AJP, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJR. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985; 318, 66–69.PubMedCrossRefGoogle Scholar
  38. 38.
    Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989; 264, 17374–17378.PubMedGoogle Scholar
  39. 39.
    Apte SS, Mattei MG, Olsen BR. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and the mapping of the TIMP-3 gene to chromosome 22. Genomics 1994; 19, 86–90.PubMedCrossRefGoogle Scholar
  40. 40.
    Greene J, Wang MS, Liu YLE, Raymond LA, Rosen C, Shi YNE. Molecular cloning and characterisation of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271, 30375–30380.PubMedCrossRefGoogle Scholar
  41. 41.
    Galis ZS, Muszynski M, Sukhova G, et al. Cytokinestimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75, 181–189.PubMedGoogle Scholar
  42. 42.
    Gersh I, Catchpole HR. The organization of ground substance and basement membrane and its significance in tissue injury, disease and growth. Am J Anat 1949; 85, 457–507.PubMedCrossRefGoogle Scholar
  43. 43.
    Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumorinduced host response. Am J Pathol 1996; 149, 273–282.PubMedGoogle Scholar
  44. 44.
    Basset P, Wolf C, Rouyer N, Bellocq JP, Rio MC, Chambon P. Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer 1994; 74, 1045–1049.PubMedCrossRefGoogle Scholar
  45. 45.
    Polette M, Clavel C, Muller D, Abecassis J, Binninger I, Birembaut P. Detection of mRNAs encoding collagenase 1 and stromelysin 2 in carcinomas of the head and neck by in situ hybridization. Invasion Metastasis 1991; 11, 76–83.PubMedGoogle Scholar
  46. 46.
    Ohtani H, Motohashi H, Sato H, Seiki M, Nagura H. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridisation and immunoelectron microscopy. Int J Cancer 1996; 68, 565–570.PubMedCrossRefGoogle Scholar
  47. 47.
    Zeng ZS, Guillem JG. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br J Cancer 1995; 72, 575–582.PubMedGoogle Scholar
  48. 48.
    Gallegos NC, Smales C, Savage FG, Hembry RM, Boulos PB. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg Oncol 1995; 4, 21–29.PubMedCrossRefGoogle Scholar
  49. 49.
    Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer—a novel approach from immune/inflammatory aspect. Jpn J Cancer Res 1997; 88, 72–81.PubMedGoogle Scholar
  50. 50.
    Seir CFM, Kubben FJGM, Ganesh S, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74, 413–417.Google Scholar
  51. 51.
    Chenard M-P, O'Siorain L, Shering S, et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996; 69, 448–451.PubMedCrossRefGoogle Scholar
  52. 52.
    Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2, 461–462.PubMedCrossRefGoogle Scholar
  53. 53.
    Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 14, 3133–3140.PubMedGoogle Scholar
  54. 54.
    Fong KM, Kida Y, Zimmerman PV, Smith PJ. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 1996; 2, 1369–1372.PubMedGoogle Scholar
  55. 55.
    Grignon DJ, Sakr W, Ravery V, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56, 1654–1659.PubMedGoogle Scholar
  56. 56.
    Johnson MD, Kim HR, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994; 160, 194–202.PubMedCrossRefGoogle Scholar
  57. 57.
    Schultz RM, Silberman S, Persky B, Bajkowski AS, Carmichael DF. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988; 48, 5539–5545.PubMedGoogle Scholar
  58. 58.
    Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG. Tumour cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991; 83, 775–779.PubMedCrossRefGoogle Scholar
  59. 59.
    DeClerck YA, Yean T-D, Chan D, Shimada H, Langley KE. Inhibition of tumour invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res 1991; 51, 2151–2157.PubMedGoogle Scholar
  60. 60.
    DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52, 701–708.PubMedGoogle Scholar
  61. 61.
    Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993; 157, 351–358.PubMedCrossRefGoogle Scholar
  62. 62.
    Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990; 248, 1408–1410.PubMedCrossRefGoogle Scholar
  63. 63.
    Beckett RP, Davidson AH, Drummond AH, Huxley P, Whittaker M. Recent advances in matrix metalloproteinase inhibitor research. Drug Dev Today 1996; 1, 16–26.CrossRefGoogle Scholar
  64. 64.
    Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995; 6, 967–974.PubMedGoogle Scholar
  65. 65.
    Grams F, Crimmin M, Hinnes L, et al. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry 1995; 34, 14012–14020.PubMedCrossRefGoogle Scholar
  66. 66.
    Morphy JR, Beeley NRA, Boyce BA. Potent and selective inhibitors of gelatinase A. 2. Carboxylic acids and phosphonic acid derivatives. Bioorg Med Chem Lett 1994; 4, 2747–2752.CrossRefGoogle Scholar
  67. 67.
    Beckett RP. Recent advances in the field of matrix metalloproteinase inhibitors (patent update). Exp Opin Ther Patents 1996; 6, 1305–1315.CrossRefGoogle Scholar
  68. 68.
    Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dental Res 1987; 66, 1310–1314.Google Scholar
  69. 69.
    Naito K, Nakajima S, Kanbayashi N, Okuyama A, Goto M. Inhibition of metalloproteinase activity of rheumatoid arthritis synovial cells by a new inhibitor [BE16627B; L-N-(N-hydroxy-2-isobutylsuccinamoyl)-seryl-L-valine]. Agents Actions 1993; 39, 182–186.PubMedCrossRefGoogle Scholar
  70. 70.
    Tamaki K, Tanzawa K, Kurihara S, et al. Synthesis and structure-activity relationships of gelatinase inhibitors derived from matlystatins. Chem Pharmac Bull 1995; 43, 1883–1893.Google Scholar
  71. 71.
    Reich R, Thompson EW, Iwamoto Y, et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988; 48, 3307–3312.PubMedGoogle Scholar
  72. 72.
    Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastases of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996; 56, 2815–2822.PubMedGoogle Scholar
  73. 73.
    Sledge GW, Qulali M, Goulet R, Bone EA, Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Res 1995; 87, 1546–1550.CrossRefGoogle Scholar
  74. 74.
    Strauch L. The role of collagenases in Tumour Invasion. In: Tarin D (ed.), Tissue Interactions in Carcinogenesis. New York: Academic Press 1972: 399–434.Google Scholar
  75. 75.
    Watson SA, Morris TM, Robinson G, Crimmin M, Brown PD, Hardcastle JD. Inhibition of organ invasion by metalloproteinase inhibitor, BB-94 (batimastat) in two human colon metastasis models. Cancer Res 1995; 55, 3629–3633.PubMedGoogle Scholar
  76. 76.
    Conway JG, Trexler SJ, Wakefield JA, et al. Effect of matrix metalloproteinase inhibitors on tumour growth and spontaneous metastasis. Clin Exp Metastasis 1996; 14, 115–124.PubMedCrossRefGoogle Scholar
  77. 77.
    Jain RK. Barriers to drug delivery in solid tumours. Sci Am 1994; 271, 58–65.PubMedCrossRefGoogle Scholar
  78. 78.
    Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32A, 2535–2539.Google Scholar
  79. 79.
    Parsons SL, Watson SA, Griffin NR, Steele RJC. An open phase I/II study of the oral matrix metalloproteinase inhibitor marimastat in patients with inoperable gastric cancer. Ann Oncol 1996; 7, 47.Google Scholar
  80. 80.
    An Z, Wang X, Willmott N, et al. Conversion of a highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis 1997; 15, 184–195.PubMedCrossRefGoogle Scholar
  81. 81.
    Taraboletti G, Garofalo A, Belotti D, et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87, 293–298.PubMedCrossRefGoogle Scholar
  82. 82.
    Galardy RE, Cassabone ME, Giese C, et al. Low molecular weight inhibitors in corneal ulceration. Ann NY Acad Sci 1994; 732, 315–323.PubMedCrossRefGoogle Scholar
  83. 83.
    Galardy RE, Grobelny D, Foellmer HG, Fernandez LA. Inhibition of angiogenesis by the matrix metalloproteinase inhibitor N-[2R-2-(hydroxyamido-carbonymethyl)-4-methylpentanoyl)]-L-tryptophan methylamide. Cancer Res 1994; 54, 4715–4718.PubMedGoogle Scholar
  84. 84.
    Anderson IC, Shipp MA, Docherty AJP, Teicher BA. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 1996; 56, 715–710.Google Scholar
  85. 85.
    Thomas H, Adams M. A phase I clinical trial of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin to patients with relapsed ovarian cancer (abstr). Eur J Cancer 1997; in press.Google Scholar
  86. 86.
    Macaulay VM, O'Byrne KJ, Saunders MP, et al. Phase I study of matrix metalloproteinase (MMP) inhibitor batimastat (BB-94) in patients with malignant pleural effusions. Br J Cancer 1995; 71, 11.Google Scholar
  87. 87.
    Wood ND, Aitken M, Harris S, Kitchener S, Mcclelland GR, Sharp S. The tolerability and pharmacokinetics of the cartilage protective agent (RO32-3555) in healthy male volunteers. Br J Clin Pharm 1996; 42, 676–677.Google Scholar
  88. 88.
    Millar AW, Brown PD, Moore J, et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharm 1997; in press.Google Scholar
  89. 89.
    Collier MA, Yuen GJ, Bansal SK, et al. A phase I study of the matrix metalloproteinase (MMP) inhibitor AG3340 given in single doses to healthy volunteers. Proc Am Ass Cancer Res 1997; 38, 221.Google Scholar
  90. 90.
    Rubin SC, Hoskins WJ, Hakes TB. CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 1989; 160, 667–671.PubMedGoogle Scholar
  91. 91.
    Goldenberg DM, Neville A, Carter A. CEA (carcinoembryonic antigen): its role as a marker in the management of cancer. J Cancer Res Clin Oncol 1981; 101, 239–242.PubMedCrossRefGoogle Scholar
  92. 92.
    Stamey TA, Kabalin JW, McNeal JE. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate II radical prostatectomy treated patients. J Urol 1989; 141, 1076–1083.PubMedGoogle Scholar
  93. 93.
    Steinberg W, Gelfand R, Anderson K. Comparison of the sensitivity and specificity of the CA 19-9 and CEA assays in detecting cancer of the pancreas. Gastroenterology 1986; 90, 343–349.PubMedGoogle Scholar
  94. 94.
    Primrose J, Bleiberg H, Daniel F, et al. A dosefinding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced colorectal cancer. Ann Oncol 1996; 7, 35.Google Scholar
  95. 95.
    Poole C, Adams M, Barley V, et al. A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced ovarian cancer. Ann Oncol 1996; 7, 68.Google Scholar
  96. 96.
    Millar A, Brown P. 360 patient meta-analysis of studies of marimastat, a novel matrix metalloproteinase inhibitor. Ann Oncol 1996; 7, 123.Google Scholar
  97. 97.
    Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992; 41, 29–34.PubMedCrossRefGoogle Scholar
  98. 98.
    Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma 1995; 12, 833–842.PubMedCrossRefGoogle Scholar

Copyright information

© Chapman and Hall 1998

Authors and Affiliations

  • Peter D. Brown
    • 1
  1. 1.Department of Clinical ResearchBritish Biotech Pharmaceuticals LtdOxfordUK

Personalised recommendations